Table 3 Distribution of clinicopathological characteristics according to tumour origin in 175 re-evaluated periampullary adenocarcinomas
Duodenum | Ampulla Intestinal type | Ampulla Pancreatobiliary type | Distal Bile Duct | Pancreas | All | |
|---|---|---|---|---|---|---|
n = 14 | n = 51 | n = 19 | n = 45 | n = 46 | n = 175 | |
Standardized Procedure | 5 (36%) | 7 (14%) | 5 (26%) | 18 (40%) | 11 (24%) | 46 (26%) |
Age at surgery, M (IQR) | 68 (62 – 74) | 67 (59 – 70) | 69 (62 – 75) | 64 (59 – 71) | 68 (62 – 72) | 67 (61 – 72) |
Gender, Female | 6 (43%) | 29 (57%) | 9 (47%) | 21 (47%) | 21 (46%) | 86 (49%) |
Tumour size, mm, M (IQR) | 40 (30 – 53) | 23 (15–30) | 30 (24 – 40) | 26 (22 – 35) | 30 (25 – 35) | 30 (21 – 35) |
Larger than 20 mm | 13 (93%) | 27 (53%) | 18 (95%) | 37 (82%) | 39 (85%) | 134 (77%) |
High grade | 7 (50%) | 26 (51%) | 9 (47%) | 31 (69%) | 28 (61%) | 101 (58%) |
Lymph nodes, M (IQR) | 10 (6 – 13.5) | 9 (6 – 16) | 10 (5 – 17) | 12 (8 – 16.5) | 11.5 (6.75 – 16) | 11 (6 – 16) |
10 or more lymph nodes | 8 (57%) | 25 (49%) | 10 (53%) | 30 (67%) | 27 (59%) | 100 (57%) |
Involved lymph nodes, M (IQR) | 0 (0 – 2) | 0 (0 – 2) | 2 (1 – 7) | 1 (0 – 4) | 2 (0 – 3) | 1 (0 – 3) |
pN1 | 4 (29%) | 24 (47%) | 16 (84%) | 27 (60%) | 34 (74%) | 106 (61%) |
pN2 | 2 (14%) | |||||
Perineural infiltration | 4 (29%) | 16 (31%) | 14 (74%) | 37 (82%) | 34 (74%) | 105 (60%) |
Infiltration in lymph vessels | 2 (14%) | 34 (67%) | 15 (79%) | 33 (73%) | 27 (59%) | 111 (63%) |
Infiltration in blood vessels | 0 (0.0%) | 5 (10%) | 8 (42%) | 14 (31%) | 15 (33%) | 42 (24%) |
Infiltration in peripancreatic fat | 6 (43%) | 16 (31%) | 17 (89%) | 36 (80%) | 32 (70%) | 107 (61%) |
T-stage (pTNM) | ||||||
T1 | 0 | 5 (10%) | 0 | 1 (2%) | 2 (4%) | |
T2 | 1 (7%) | 11 (22%) | 0 | 2 (4%) | 10 (22%) | |
T3 | 6 (43%) | 19 (37%) | 2 (11%) | 42 (93%) | 34 (74%) | |
T4 | 7 (50%) | 16 (31%) | 17 (89%) | 0 | 0 | |
R1 | 3 (38%) | 10 (43%) | 14 (93%) | 32 (89%) | 35 (95%) | 94 (79%) |
R0 | 5 (63%) | 13 (57%) | 1 (7%) | 4 (11%) | 2 (6%) | 25 (21%) |
Rx,uncertain margin status (n) | 6 | 28 | 4 | 9 | 9 | 56 |
Pancreatic transection margin | 1 (13%) | 1 (4%) | 1 (7%) | 5 (14%) | 10 (27%) | 18 (15%) |
DBD transection margin | 0 | 0 | 0 | 2 (6%) | 1 (3%) | 3 (3%) |
SMA-margin | 0 | 0 | 0 | 10 (28%) | 2 (5%) | 12 (10%) |
Posterior margin | 2 (25%) | 6 (26%) | 6 (40%) | 17 (47%) | 11 (30%) | 42 (35%) |
SMV-margin | 1 (13%) | 0 | 0 | 13 (36%) | 18 (49%) | 32 (27%) |
Anterior margin | 1 (13%) | 1 (4%) | 2 (13%) | 5 (14%) | 5 (14%) | 14 (12%) |
5-year OS, M (IQR), months | n.r. (37 - n.r.) | 53 (26 - n.r.) | 26 (15–40) | 25 (16 - n.r.) | 25 (13–42) | 30 (17-n.r.) |